Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor.

Ito T, Okusaka T, Nishida T, Yamao K, Igarashi H, Morizane C, Kondo S, Mizuno N, Hara K, Sawaki A, Hashigaki S, Kimura N, Murakami M, Ohki E, Chao RC, Imamura M.

Invest New Drugs. 2019 Jun;37(3):591. doi: 10.1007/s10637-019-00757-9.

PMID:
30903344
2.

Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor.

Ito T, Okusaka T, Nishida T, Yamao K, Igarashi H, Morizane C, Kondo S, Mizuno N, Hara K, Sawaki A, Hashigaki S, Kimura N, Murakami M, Ohki E, Chao RC, Imamura M.

Invest New Drugs. 2013 Oct;31(5):1265-74. doi: 10.1007/s10637-012-9910-y. Epub 2012 Dec 27. Erratum in: Invest New Drugs. 2019 Jun;37(3):591.

3.

Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study.

Ito T, Tori M, Hashigaki S, Kimura N, Sato K, Ohki E, Sawaki A, Okusaka T.

Jpn J Clin Oncol. 2019 Apr 1;49(4):354-360. doi: 10.1093/jjco/hyz009.

4.

Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.

Raymond E, Kulke MH, Qin S, Yu X, Schenker M, Cubillo A, Lou W, Tomasek J, Thiis-Evensen E, Xu JM, Croitoru AE, Khasraw M, Sedlackova E, Borbath I, Ruff P, Oberstein PE, Ito T, Jia L, Hammel P, Shen L, Shrikhande SV, Shen Y, Sufliarsky J, Khan GN, Morizane C, Galdy S, Khosravan R, Fernandez KC, Rosbrook B, Fazio N.

Neuroendocrinology. 2018;107(3):237-245. doi: 10.1159/000491999. Epub 2018 Jul 10.

PMID:
29991024
5.

Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential.

Delbaldo C, Faivre S, Dreyer C, Raymond E.

Ther Adv Med Oncol. 2012 Jan;4(1):9-18. doi: 10.1177/1758834011428147.

6.

Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms.

Mizuno Y, Kudo A, Akashi T, Akahoshi K, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Tanaka S, Tateishi U, Tanabe M.

J Cancer Res Clin Oncol. 2018 Jun;144(6):1155-1163. doi: 10.1007/s00432-018-2636-2. Epub 2018 Mar 30.

PMID:
29602973
7.

FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors.

Blumenthal GM, Cortazar P, Zhang JJ, Tang S, Sridhara R, Murgo A, Justice R, Pazdur R.

Oncologist. 2012;17(8):1108-13. doi: 10.1634/theoncologist.2012-0044. Epub 2012 Jul 26.

8.

Activity of sunitinib in patients with advanced neuroendocrine tumors.

Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS.

J Clin Oncol. 2008 Jul 10;26(20):3403-10. doi: 10.1200/JCO.2007.15.9020.

PMID:
18612155
9.

Safety and efficacy of sunitinib in patients with unresectable pancreatic neuroendocrine tumors.

Wiedmann MW, Mössner J.

Clin Med Insights Oncol. 2012;6:381-93. doi: 10.4137/CMO.S7350. Epub 2012 Nov 20.

10.

Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.

Mujica-Mota R, Varley-Campbell J, Tikhonova I, Cooper C, Griffin E, Haasova M, Peters J, Lucherini S, Talens-Bou J, Long L, Sherriff D, Napier M, Ramage J, Hoyle M.

Health Technol Assess. 2018 Sep;22(49):1-326. doi: 10.3310/hta22490.

11.

Disseminated intravascular coagulation following administration of sunitinib.

Olivo A, Noël N, Besse B, Taburet AM, Lambotte O.

Mol Clin Oncol. 2016 Jul;5(1):121-123. Epub 2016 May 11.

12.

Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors.

Strosberg JR, Fisher GA, Benson AB, Anthony LB, Arslan B, Gibbs JF, Greeno E, Iyer RV, Kim MK, Maples WJ, Philip PA, Wolin EM, Cherepanov D, Broder MS.

World J Gastroenterol. 2015 Feb 28;21(8):2450-9. doi: 10.3748/wjg.v21.i8.2450. Review.

13.

First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study.

Tsuji Y, Satoh T, Tsuji A, Muro K, Yoshida M, Nishina T, Nagase M, Komatsu Y, Kato T, Miyata Y, Mizutani N, Hashigaki S, Lechuga MJ, Denda T.

Cancer Sci. 2012 Aug;103(8):1502-7. doi: 10.1111/j.1349-7006.2012.02320.x. Epub 2012 Jun 14.

14.

Sunitinib is effective and tolerable in Chinese patients with advanced pancreatic neuroendocrine tumors: a multicenter retrospective study in China.

Wang Y, Jin K, Tan H, Zhang P, Yang Q, Wang W, Li J, Shao C, Xue L, Feng S, Chen M, Yu X, Chen J.

Cancer Chemother Pharmacol. 2017 Sep;80(3):507-516. doi: 10.1007/s00280-017-3367-9. Epub 2017 Jul 13.

PMID:
28707013
15.

Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): When cytoreduction is the aim. A critical review with meta-analysis.

Pozzari M, Maisonneuve P, Spada F, Berruti A, Amoroso V, Cella CA, Laffi A, Pellicori S, Bertani E, Fazio N.

Cancer Treat Rev. 2018 Dec;71:39-46. doi: 10.1016/j.ctrv.2018.10.008. Epub 2018 Oct 13. Review.

PMID:
30352319
17.

Severe perirenal hematoma in a patient with a single kidney treated with sunitinib for metastatic pancreatic neuroendocrine tumor.

Zugazagoitia J, Sastre J, Barrera J, García B, Díaz-Rubio E.

J Cancer Res Ther. 2012 Apr-Jun;8(2):303-5. doi: 10.4103/0973-1482.98997.

18.

Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors.

Ito T, Honma Y, Hijioka S, Kudo A, Fukutomi A, Nozaki A, Kimura Y, Motoi F, Isayama H, Komoto I, Hisamatsu S, Nakajima A, Shimatsu A.

Invest New Drugs. 2017 Aug;35(4):499-508. doi: 10.1007/s10637-017-0466-8. Epub 2017 May 3.

19.

Sunitinib in pancreatic neuroendocrine tumors.

Raymond E, Hammel P, Dreyer C, Maatescu C, Hentic O, Ruszniewski P, Faivre S.

Target Oncol. 2012 Jun;7(2):117-25. doi: 10.1007/s11523-012-0220-2. Epub 2012 Jun 2. Review.

PMID:
22661319
20.

Pancreatic neuroendocrine tumors: a comprehensive review.

Zhou C, Zhang J, Zheng Y, Zhu Z.

Int J Cancer. 2012 Sep 1;131(5):1013-22. doi: 10.1002/ijc.27543. Epub 2012 Apr 16. Review.

Supplemental Content

Support Center